UK-headquartered IONTAS Limited, a company specialising in the discovery and optimisation of fully human antibodies, has published a research paper in Nature Communications in collaboration with the Technical University of Denmark and the Instituto Clodomiro Picado of the University of Costa Rica describing the development of a panel of human antibodies that neutralise elements of black mamba snake toxin in an in-vivo model. Snakebite envenoming has recently been introduced on the World Health Organization’s list of neglected tropical diseases due to its high disease burden.
The proof of concept research described in Nature Communications identifies key components in the black mamba’s venom that contribute to venom toxicity, which include dendrotoxins. Human antibodies were generated to these dendrotoxins using IONTAS Phage Display Technology and mixtures of IgG-formatted human antibodies were then shown to protect mice from dendrotoxin-mediated neurotoxicity in vivo.
For further information about IONTAS Limited visit www.iontas.co.uk
Latest from Tom Mulligan
- Concept Life Sciences forms Scientific Advisory Board
- Sangamo finalises TxCell acquisition
- Polyplus-transfection introduces new nanoparticle DNA transfection reagent
- The 6th SGS Biopharma Day Seminar: a new early-phase clinical trials paradigm
- Blacktrace expands its presence in Japan with new office in Kanagawa
- MaSTherCell doubles production capacity
- Absolute Antibody expands production facilities
- Optibrium and University of Nottingham collaborate on innovative teaching programme
- Diamond Pharma Services wins both Futures and Support categories at TOPRA Awards
- Droplet microfluidics offers new approach for studying plant cell biomechanics